Ann: Half Yearly Report and Accounts, page-4

@ 30/6/18 ,
Cash and cash equivalents at the end of the period  $3.204 million
Thanks Yacov for the loan!

~
Looking healthy

~
p6
REVIEW AND RESULTS OF OPERATIONS

G Medical Innovations Holdings Ltd (The Company) reports on half year results as of 30 June 2018. The Company had a net loss of US$ 8. 509 million versus US$ 21.740 million in the comparable period of 2017.

The Company generated first revenues of US$ 1.001 million, which were offset by the following operating expenses:

•R&D, S&M and G&A expenses went up from US$ 3.136 million in H1 2017 to US$ 9.067 million.
That includes:-

Expenses of US$ 0.970 million attributed to the amortization of intangible assets while acquiring CardioStaff (renamed G Medical Diagnostic Services).-

From the balance of approximately US $5.000 million, about US$ 3.200 million is attributed to CardioStaff activities in the US which was purchased close to the end of 2017. The rest is attributed to otheroperational expenses incurred to meet the Company's development (including FDA and CFDA regulatory requirements) and business goals
.
The revenues were mainly generated from G Medical Diagnostic Services (GMedDx)

. The IDTF offers extended Holter (AECG) monitoring services and recently launched a service utilizing Mobile Cardiac Telemetry (MCT) monitors.

We have experienced 50-60% month over month growth in enrolments.

Significant resources were invested to bring an excellent clinical reporting portfolio with comprehensive reporting capabilities.

MedDx is also pursuing more payor contracts, including several key strategic agreements.

~